Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMTKSVO)

Drug Name
T0070907 Drug Info
Synonyms
2-Chloro-5-nitro-N-4-pyridinylbenzamide; 313516-66-4; 2-CHLORO-5-NITRO-N-4-PYRIDINYLBENZAMIDE; 2-chloro-5-nitro-N-(pyridin-4-yl)benzamide; T 0070907; T-0070907; 2-chloro-5-nitro-N-pyridin-4-ylbenzamide; 2-Chloro-5-nitro-N-(4-pyridyl)benzamide; CHEMBL510698; Benzamide, 2-chloro-5-nitro-N-4-pyridinyl-; 2-chloro-5-nitro-n-4-pyridinyl-benzamide; SR-01000392700; AC1MCROG; Oprea1_586106; ZINC3381; GTPL3444; SCHEMBL2128178; CTK6H1028; KS-00000MYU; CHEBI:92553; DTXSID30380504; MolPort-001-763-336; FRPJSHKMZHWJBE-UHFFFAOYSA-N; HMS3268J16; HMS3651P21; HMS3262J21; T 0070907
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
2777391
ChEBI ID
CHEBI:92553
CAS Number
CAS 313516-66-4
TTD Drug ID
DMTKSVO

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting PPAR-gamma messenger RNA (PPARG mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Bardoxolone methyl DMODA2X Mixed connective tissue disease 4A43.3 Phase 3 [5]
AD-5075 DM1SLJ9 Type-2 diabetes 5A11 Terminated [6]
2-chloro-5-nitro-N-phenylbenzamide DMUGQIV Discovery agent N.A. Investigative [7]
L-783483 DM6OTGE Discovery agent N.A. Investigative [8]
LG100754 DMEK4FY Discovery agent N.A. Investigative [9]
L-796449 DMWTGQM Discovery agent N.A. Investigative [10]
L-165461 DMKBSGN Discovery agent N.A. Investigative [10]
AD-5061 DM5WV13 Discovery agent N.A. Investigative [11]
TZD18 DMVCHOX Discovery agent N.A. Investigative [12]
(9Z,12E)-12-nitrooctadeca-9,12-dienoic acid DM2REIN Discovery agent N.A. Investigative [13]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lipoprotein lipase (LPL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Paclitaxel DMLB81S Breast carcinoma Approved [14]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [15]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [16]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [17]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [18]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [19]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [20]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [21]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [22]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [21]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Fatty acid-binding protein, adipocyte (FABP4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [23]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [24]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [25]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [26]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [23]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [29]
Fenofibrate DMFKXDY Coronary atherosclerosis Approved [30]
Capsaicin DMGMF6V Back pain ME84.Z Approved [31]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By CCAAT/enhancer-binding protein alpha (CEBPA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [32]
Quercetin DM3NC4M Obesity 5B81 Approved [33]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [34]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [35]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [36]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [21]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [37]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [27]
Efavirenz DMC0GSJ Human immunodeficiency virus infection 1C62 Approved [21]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [38]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Lipid transferase CIDEC (CIDEC)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Quercetin DM3NC4M Obesity 5B81 Approved [33]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [39]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [27]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [40]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [41]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [42]
DNCB DMDTVYC Immune System disease 4A01-4B41 Phase 2 [43]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [33]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Chorion-specific transcription factor GCMa (GCM1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [45]
Leflunomide DMR8ONJ Arthritis FA20 Approved [46]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [28]
Rosiglitazone DMILWZR Chronic kidney disease GB61 Approved [3]
DTI-015 DMXZRW0 Brain cancer 2A00 Approved [47]
Urethane DM7NSI0 N. A. N. A. Phase 4 [48]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [49]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [50]
Forskolin DM6ITNG Solid tumour/cancer 2A00-2F9Z Investigative [51]
CHLORPYRIFOS DMKPUI6 Discovery agent N.A. Investigative [52]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Testosterone DM7HUNW Hot flushes GA30 Approved [53]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [53]
Gefitinib DM15F0X Colon adenocarcinoma Approved [54]
Sunitinib DMCBJSR Acute undifferentiated leukemia Approved [14]
Rosuvastatin DMMIQ7G Arteriosclerosis BD40 Approved [55]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [56]
Methotrexate DM2TEOL Anterior urethra cancer Approved [57]
Quercetin DM3NC4M Obesity 5B81 Approved [58]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [59]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [60]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
PPAR-gamma messenger RNA (PPARG mRNA) TTT2SVW PPARG_HUMAN Antagonist [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Gene/Protein Processing [3]
CCAAT/enhancer-binding protein alpha (CEBPA) OTOM9OE4 CEBPA_HUMAN Gene/Protein Processing [4]
Chorion-specific transcription factor GCMa (GCM1) OT5CPAUT GCM1_HUMAN Gene/Protein Processing [3]
Fatty acid-binding protein, adipocyte (FABP4) OT3DKFOU FABP4_HUMAN Gene/Protein Processing [4]
Lipid transferase CIDEC (CIDEC) OTMDZ56K CIDEC_HUMAN Gene/Protein Processing [4]
Lipoprotein lipase (LPL) OTTW0267 LIPL_HUMAN Gene/Protein Processing [4]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 3444).
2 T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem. 2002 May 31;277(22):19649-57.
3 Regulation of the placental BCRP transporter by PPAR gamma. J Biochem Mol Toxicol. 2017 May;31(5):10.1002/jbt.21880. doi: 10.1002/jbt.21880. Epub 2016 Nov 23.
4 Effects of Perinatal Exposure to Dibutyltin Chloride on Fat and Glucose Metabolism in Mice, and Molecular Mechanisms, in Vitro. Environ Health Perspect. 2018 May 21;126(5):057006. doi: 10.1289/EHP3030. eCollection 2018 May.
5 A synthetic triterpenoid, 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid (CDDO), is a ligand for the peroxisome proliferator-activated receptor gamma. Mol Endocrinol. 2000 Oct;14(10):1550-6.
6 Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice. Endocrinology. 1996 Oct;137(10):4189-95.
7 Tryptophan-containing dipeptide derivatives as potent PPARgamma antagonists: design, synthesis, biological evaluation, and molecular modeling. Eur J Med Chem. 2008 Dec;43(12):2699-716.
8 Novel peroxisome proliferator-activated receptor (PPAR) gamma and PPARdelta ligands produce distinct biological effects. J Biol Chem. 1999 Mar 5;274(10):6718-25.
9 The antidiabetic agent LG100754 sensitizes cells to low concentrations of peroxisome proliferator-activated receptor gamma ligands. J Biol Chem. 2002 Apr 12;277(15):12503-6.
10 Phenylacetic acid derivatives as hPPAR agonists. Bioorg Med Chem Lett. 2003 Apr 7;13(7):1277-80.
11 A novel oxyiminoalkanoic acid derivative, TAK-559, activates human peroxisome proliferator-activated receptor subtypes. Eur J Pharmacol. 2004 Jul 8;495(1):17-26.
12 A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis. Endocrinology. 2004 Apr;145(4):1640-8.
13 Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by nitroalkene fatty acids: importance of nitration position and degree ... J Med Chem. 2009 Aug 13;52(15):4631-9.
14 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
15 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
16 Oxidative Stress Alters miRNA and Gene Expression Profiles in Villous First Trimester Trophoblasts. Biomed Res Int. 2015;2015:257090. doi: 10.1155/2015/257090. Epub 2015 Aug 3.
17 Effect of troglitazone on plasma lipid metabolism and lipoprotein lipase. Br J Clin Pharmacol. 1999 Apr;47(4):433-9. doi: 10.1046/j.1365-2125.1999.00920.x.
18 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
19 Morphological and molecular course of mitochondrial pathology in cultured human cells exposed long-term to Zidovudine. Environ Mol Mutagen. 2007 Apr-May;48(3-4):179-89. doi: 10.1002/em.20245.
20 Global effects of inorganic arsenic on gene expression profile in human macrophages. Mol Immunol. 2009 Feb;46(4):649-56.
21 Effects of nevirapine and efavirenz on human adipocyte differentiation, gene expression, and release of adipokines and cytokines. Antiviral Res. 2011 Aug;91(2):112-9. doi: 10.1016/j.antiviral.2011.04.018. Epub 2011 May 17.
22 Genomic and proteomic analysis of the effects of cannabinoids on normal human astrocytes. Brain Res. 2008 Jan 29;1191:1-11.
23 Rofecoxib modulates multiple gene expression pathways in a clinical model of acute inflammatory pain. Pain. 2007 Mar;128(1-2):136-47.
24 Induction of solid tumor differentiation by the peroxisome proliferator-activated receptor-gamma ligand troglitazone in patients with liposarcoma. Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):3951-6. doi: 10.1073/pnas.96.7.3951.
25 Retinoic acid-induced downmodulation of telomerase activity in human cancer cells. Exp Mol Pathol. 2005 Oct;79(2):108-17.
26 Adipocyte differentiation, mitochondrial gene expression and fat distribution: differences between zidovudine and tenofovir after 6 months. Antivir Ther. 2009;14(8):1089-100. doi: 10.3851/IMP1457.
27 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
28 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
29 Ursodeoxycholic acid but not tauroursodeoxycholic acid inhibits proliferation and differentiation of human subcutaneous adipocytes. PLoS One. 2013 Dec 3;8(12):e82086. doi: 10.1371/journal.pone.0082086. eCollection 2013.
30 Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages. Metabolism. 2003 May;52(5):652-7. doi: 10.1053/meta.2003.50100.
31 Induction of the endoplasmic reticulum stress protein GADD153/CHOP by capsaicin in prostate PC-3 cells: a microarray study. Biochem Biophys Res Commun. 2008 Aug 8;372(4):785-91.
32 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
33 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
34 Species-specific toxicity of diclofenac and troglitazone in primary human and rat hepatocytes. Chem Biol Interact. 2009 Apr 15;179(1):17-24.
35 C/EBPalpha inactivation in FAK-overexpressed HL-60 cells impairs cell differentiation. Cell Signal. 2006 Jul;18(7):955-63. doi: 10.1016/j.cellsig.2005.08.014. Epub 2005 Oct 14.
36 Arsenic trioxide promotes senescence and regulates the balance of adipogenic and osteogenic differentiation in human mesenchymal stem cells. Acta Biochim Biophys Sin (Shanghai). 2011 Mar;43(3):204-9. doi: 10.1093/abbs/gmq130. Epub 2011 Jan 21.
37 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
38 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
39 Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period. Toxicol In Vitro. 2015 Dec 25;30(1 Pt A):27-35.
40 Effects of chronic rosiglitazone therapy on gene expression in human adipose tissue in vivo in patients with type 2 diabetes. J Clin Endocrinol Metab. 2007 Feb;92(2):720-4.
41 Dexamethasone and the inflammatory response in explants of human omental adipose tissue. Mol Cell Endocrinol. 2010 Feb 5;315(1-2):292-8.
42 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
43 Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. Mol Immunol. 2007 May;44(12):3222-33.
44 Microarray analysis of bisphenol A-induced changes in gene expression in human oral epithelial cells. Acta Biochim Biophys Sin (Shanghai). 2007 Nov;39(11):879-84. doi: 10.1111/j.1745-7270.2007.00351.x.
45 The psychoactive compound of Cannabis sativa, (9)-tetrahydrocannabinol (THC) inhibits the human trophoblast cell turnover. Toxicology. 2015 Aug 6;334:94-103. doi: 10.1016/j.tox.2015.06.005. Epub 2015 Jun 9.
46 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
47 Gene expression profile induced by BCNU in human glioma cell lines with differential MGMT expression. J Neurooncol. 2005 Jul;73(3):189-98.
48 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
49 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
50 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
51 Effects of Bisphenol A on endogenous retroviral envelopes expression and trophoblast fusion in BeWo cells. Reprod Toxicol. 2019 Oct;89:35-44. doi: 10.1016/j.reprotox.2019.07.001. Epub 2019 Jul 3.
52 Chlorpyrifos modifies the expression of genes involved in human placental function. Reprod Toxicol. 2012 Jun;33(3):331-8. doi: 10.1016/j.reprotox.2012.01.003. Epub 2012 Jan 21.
53 Localization of breast cancer resistance protein (Bcrp) in endocrine organs and inhibition of its transport activity by steroid hormones. Cell Tissue Res. 2012 Aug;349(2):551-63. doi: 10.1007/s00441-012-1417-5. Epub 2012 May 13.
54 Pharmacogenetics of ABCG2 and adverse reactions to gefitinib. J Natl Cancer Inst. 2006 Dec 6;98(23):1739-42.
55 ABCG2 polymorphism is associated with the low-density lipoprotein cholesterol response to rosuvastatin. Clin Pharmacol Ther. 2010 May;87(5):558-62.
56 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
57 Proteomic identification of differentially expressed proteins associated with the multiple drug resistance in methotrexate-resistant human breast cancer cells. Int J Oncol. 2014 Jul;45(1):448-58.
58 Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem. 2008 Aug;106(4):1855-65. doi: 10.1111/j.1471-4159.2008.05537.x. Epub 2008 Jul 4.
59 Differential gene expression in human hepatocyte cell lines exposed to the antiretroviral agent zidovudine. Arch Toxicol. 2014 Mar;88(3):609-23. doi: 10.1007/s00204-013-1169-3. Epub 2013 Nov 30.
60 Chronic imatinib mesylate exposure leads to reduced intracellular drug accumulation by induction of the ABCG2 (BCRP) and ABCB1 (MDR1) drug transport pumps. Cancer Biol Ther. 2005 Jul;4(7):747-52.